Sera Prognostics, Inc., (SERA): Price and Financial Metrics

Sera Prognostics, Inc., (SERA): $3.76

-0.08 (-2.08%)

POWR Rating

Component Grades













SERA Stock Summary

  • SERA's price/sales ratio is 435.23; that's higher than the P/S ratio of 99.05% of US stocks.
  • With a year-over-year growth in debt of 1,706.25%, SERA PROGNOSTICS INC's debt growth rate surpasses 98.68% of about US stocks.
  • Revenue growth over the past 12 months for SERA PROGNOSTICS INC comes in at 226.83%, a number that bests 96.65% of the US stocks we're tracking.
  • Stocks with similar financial metrics, market capitalization, and price volatility to SERA PROGNOSTICS INC are ARDX, SOPH, RXST, MOTS, and AMST.
  • To check out SERA PROGNOSTICS INC's SEC filings, go to the company's page on browse-edgar?action=getcompany&CIK=0001534969.

SERA Valuation Summary

  • SERA's EV/EBIT ratio is -2; this is 130.3% lower than that of the median Healthcare stock.
  • Over the past 21 months, SERA's price/earnings ratio has gone up 15.7.

Below are key valuation metrics over time for SERA.

Stock Date P/S P/B P/E EV/EBIT
SERA 2023-03-24 435.1 1.2 -2.6 -2.0
SERA 2023-03-23 438.8 1.2 -2.7 -2.0
SERA 2023-03-22 470.5 1.3 -2.9 -2.2
SERA 2023-03-21 570.3 1.2 -2.8 -2.0
SERA 2023-03-20 562.0 1.2 -2.7 -1.9
SERA 2023-03-17 575.5 1.2 -2.8 -2.0

SERA Price Target

For more insight on analysts targets of SERA, see our SERA price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $18.00 Average Broker Recommendation 1.17 (Strong Buy)

SERA Stock Price Chart Interactive Chart >

Price chart for SERA

SERA Price/Volume Stats

Current price $3.76 52-week high $4.25
Prev. close $3.84 52-week low $1.10
Day low $3.76 Volume 1,919
Day high $3.85 Avg. volume 1,371,134
50-day MA $2.90 Dividend yield N/A
200-day MA $1.99 Market Cap 116.62M

Sera Prognostics, Inc., (SERA) Company Bio

Sera Prognostics, Inc., a health diagnostic company, discovers, develops, and commercializes biomarker tests for the early prediction of preterm birth risk and other complications of pregnancy. It develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.

SERA Latest News Stream

Event/Time News Detail
Loading, please wait...

SERA Latest Social Stream

Loading social stream, please wait...

View Full SERA Social Stream

Latest SERA News From Around the Web

Below are the latest news stories about SERA PROGNOSTICS INC that investors may wish to consider to help them evaluate SERA as an investment opportunity.

All You Need to Know About Sera Prognostics, Inc. (SERA) Rating Upgrade to Buy

Sera Prognostics, Inc. (SERA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Yahoo | March 27, 2023

Sera Prognostics, Inc. (NASDAQ:SERA) Q4 2022 Earnings Call Transcript

Sera Prognostics, Inc. (NASDAQ:SERA) Q4 2022 Earnings Call Transcript March 22, 2023 Operator: Good afternoon, and welcome to the Sera Prognostics Conference Call to Review Fourth Quarter and Fiscal Year 2022 results. At this time, all participants are in listen-only mode. We will be facilitating a question-and-answer session towards the end of today’s call. As […]

Yahoo | March 27, 2023

Sera Prognostics Full Year 2022 Earnings: Revenues Miss Expectations

Sera Prognostics ( NASDAQ:SERA ) Full Year 2022 Results Key Financial Results Net loss: US$44.2m (loss widened by 26...

Yahoo | March 24, 2023

Sera Prognostics, Inc. (SERA) Reports Q4 Loss, Lags Revenue Estimates

Sera Prognostics, Inc. (SERA) delivered earnings and revenue surprises of 26.19% and 50%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | March 22, 2023


Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the fourth quarter and full year 2022 ended December 31, 2022.

Yahoo | March 22, 2023

Read More 'SERA' Stories Here

SERA Price Returns

1-mo 7.43%
3-mo 198.41%
6-mo 135.00%
1-year -0.79%
3-year N/A
5-year N/A
YTD 198.41%
2022 -81.66%
2021 N/A
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.773 seconds.